Use of Bacopa monnieri in the Treatment of Dementia Due to Alzheimer Disease: Systematic Review of Randomized Controlled Trials.

The short version

This systematic review pooled the human clinical trial evidence on Bacopa monnieri (Brahmi), a plant long used in Ayurvedic medicine and studied in animal models for its potential to protect brain cells, to ask whether it actually helps people with Alzheimer's disease or the memory decline that often precedes it (mild cognitive impairment). The comparison point was donepezil, the standard prescription drug for Alzheimer's, which modestly eases symptoms but does not slow the underlying disease. The review searched five major databases and trial registries through January 2021 and found only 5 trials, involving a total of roughly 200-plus participants, that directly tested Bacopa in people already diagnosed with Alzheimer's or mild cognitive impairment (most prior Bacopa research had studied healthy adults instead). The trials varied widely in dose, length (2 to 12 months), and whether Bacopa was given alone or mixed with other herbs and nutrients, so the researchers could not statistically combine the results and instead described each trial's findings individually. Study quality was assessed using the Cochrane risk-of-bias tool and graded overall with the GRADE system. The five trials told an inconsistent story. The largest head-to-head comparison against donepezil found no difference between the two through nine months, with donepezil only pulling ahead at the one-year mark in a trial that had to stop early due to poor participant recruitment (34 of a planned 48). Two other trials reported improvement, but Bacopa was just one ingredient in a multi-herb blend in both, so the benefit cannot be pinned on Bacopa specifically. A fourth trial had questionable methods, including dropping 15 participants from the analysis after the fact without explanation. None of the five trials reported serious safety concerns with Bacopa. Overall, the reviewers found no solid evidence that Bacopa monnieri outperforms placebo or donepezil for Alzheimer's disease or mild cognitive impairment, rating the certainty of the existing evidence as very low. This does not mean Bacopa definitely does not help, only that the trials done so far are too few, too small, and too inconsistent to say either way. The authors call for larger, well-designed trials testing Bacopa on its own before any conclusion about its use in dementia can be drawn.

Key findings

• A systematic review of 5 randomized trials found no high-quality evidence that Bacopa monnieri (Brahmi) is more effective than a placebo or the Alzheimer's drug donepezil for people with Alzheimer's disease or mild cognitive impairment.
• The largest head-to-head trial against donepezil (34 participants) found no difference between the two treatments through 9 months, with donepezil only showing a statistical edge at the 12-month endpoint, in a trial that had to stop early due to slow recruitment.
• Two of the five trials that reported improvement gave Bacopa as part of a multi-ingredient herbal or nutraceutical blend, so any benefit seen cannot be attributed to Bacopa on its own.
• The overall certainty of the evidence was rated very low by the GRADE system, reflecting small sample sizes, short follow-up periods, and methodological weaknesses such as one trial excluding 15 participants from analysis without explanation.
• No major safety issues were reported with Bacopa monnieri across any of the five trials, though the evidence base is too limited to draw firm conclusions about either its benefit or its long-term safety in people with dementia.

Common questions